SLC5A2 and diabetes mellitus: It is noteworthy in this context that newer drugs for diabetes management such as the sodium–glucose co-transporter-2 (SGLT2) inhibitors, which promote glucose loss by the kidney, may predispose patients with type 2 diabetes to DKA [35].